3-amino-4-(7-aminomethyl-3,4-dihydro-1H-isoquinolin-2-yl)-cyclobut-3-ene-1,2-dione hydrochloride | 903556-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 3-amino-4-(7-aminomethyl-3,4-dihydro-1H-isoquinolin-2-yl)-cyclobut-3-ene-1,2-dione hydrochloride
• 英文别名: 3-amino-4-(7-aminomethyl-3,4-dihydroisoquinolin-2(1H)-yl)cyclobut-3-ene-1,2-dione hydrochloride；3-amino-4-[7-(aminomethyl)-3,4-dihydro-1H-isoquinolin-2-yl]cyclobut-3-ene-1,2-dione;hydrochloride
• CAS: 903556-98-9
• 化学式: C₁₄H₁₅N₃O₂*ClH
• 分子量: 293.753
• InChiKey: UPLGMFPGMHMGQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.31
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  89.4
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-[[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]carbamoyl]pyrimidine-4-carboxylic acid 、 3-amino-4-(7-aminomethyl-3,4-dihydro-1H-isoquinolin-2-yl)-cyclobut-3-ene-1,2-dione hydrochloride 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以82%的产率得到6-N-[[2-(2-amino-3,4-dioxocyclobuten-1-yl)-3,4-dihydro-1H-isoquinolin-7-yl]methyl]-4-N-[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]pyrimidine-4,6-dicarboxamide
  参考文献：
  名称：

  Multicyclic bis-amide MMP inhibitors

  摘要：

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。

  公开号：

  US20060173183A1
• 作为产物：
  描述：

  tert-butyl N-[[2-(2-amino-3,4-dioxocyclobuten-1-yl)-3,4-dihydro-1H-isoquinolin-7-yl]methyl]carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 14.0h， 生成 3-amino-4-(7-aminomethyl-3,4-dihydro-1H-isoquinolin-2-yl)-cyclobut-3-ene-1,2-dione hydrochloride
  参考文献：
  名称：

  Substituted bis-amide metalloprotease inhibitors

  摘要：

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。

  公开号：

  US20070155739A1

文献信息

• Substituted bis-amide metalloprotease inhibitors
  申请人：Sucholeiki Irving

  公开号：US20070155739A1

  公开（公告）日：2007-07-05

  This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。
• Heterobicyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080261968A1

  公开（公告）日：2008-10-23

  The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

  本发明涉及含有杂环的药物，特别是含有杂环的金属蛋白酶抑制剂。更具体地说，本发明提供了一种新型的杂环MMP-3、MMP-8和/或MMP-13抑制剂，其在与当前已知的MMP-13、MMP-8和MMP-3抑制剂相比具有更高的效力和选择性。
• WO2008/63671
  申请人：——

  公开号：——

  公开（公告）日：——
• Extra Binding Region Induced by Non-Zinc Chelating Inhibitors into the S₁′ Subsite of Matrix Metalloproteinase 8 (MMP-8)
  作者：Giorgio Pochetti、Roberta Montanari、Christian Gege、Carine Chevrier、Arthur G. Taveras、Fernando Mazza

  DOI：10.1021/jm801166j

  日期：2009.2.26

  The mode of binding and the activity of the first two non-zinc chelating, potent, and selective inhibitors of human neutrophil collagenase are reported. The crystal structures of the catalytic domain of MMP-8, respectively complexed with each inhibitor, reveals that both ligands are deeply inserted into the primary specificity subsite S(1)', where they induce a similar conformational change of the surrounding loop that is endowed with the main specificity determinants of MMPs. Accord to this rearrangement, both inhibitors remove the floor of the pocket formed by the Y227 side-chain, rendering available an extra binding region never explored before. The present data show that potent and more selective inhibitors can be obtained by developing ligands able to interact with the selectivity regions of the enzyme rather than with the catalytic zinc ion, which is the common feature of all MMP members.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Alantos Pharmaceuticals Holding, Inc.

  公开号：EP2094671A1

  公开（公告）日：2009-09-02